Non-small cell lung cancer emerging therapies

The Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would expand the NSCLC market size enabling the drug manufacturers to penetrate more into the market. Companies across the globe are diligently working toward the development of new therapies for NSCLC treatment.

The launch of below mentioned emerging therapies along with others is expected to significantly impact the treatment scenario of Non-Small Cell Lung Cancer in the coming years, 2019–2028.

Tislelizumab, an investigational humanized IgG4 anti-PD-1 monoclonal antibody under development by a Chinese-American pharmaceutical BeiGene. The trials are in Phase III at present, and the drug is being developed as monotherapy for Non-Small Cell Lung Cancer treatment.

Pinabulin, a drug candidate of BeyondSpring Pharma, is a late-stage agent in Phase III clinical trials. The company is planning to file NDA in the US in 2020. The therapy is also under simulation in the combination therapy with nivolumab, ipilimumab, and pembrolizumab for NSCLC and as second- and third-line therapy in combination with docetaxel for advanced NSCLC.

Capmatinib, a drug in Phase II clinical trials by Novartis, is an investigational, oral, and selective MET inhibitor. The FDA granted the therapy Breakthrough Therapy designation in May 2018 for the treatment of patients with metastatic NSCLC. This product as licensed to Novartis by Incyte Corporation. Under this Agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.

HS-110 (also known as viagenpumatucel-L) is a biologic product which stimulates the patient’s own T-cells to target cancer. Heat Biologics is conducting the trials in combination with Bristol-Myers Squibb’s checkpoint inhibitor, Nivolumab in patients with NSCLC. It is made of a cancer cell line that has been genetically modified using ImPACT technology platform. The therapy is in Phase II trials.

Transgene is developing a vaccine, TG4010, that consists of a vector, Modified Vaccinia Ankara virus (MVA). The therapy expresses the MUC1 antigen and interleukin 2 (IL-2), a cytokine stimulating the immune system. The vaccine is in phase II trial for the treatment of Non-small cell lung cancer.

The NSCLC market is anticipated to advance forward owing to the launch of upcoming therapies, and advanced diagnostics methodologies.